Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;12(1):29-38.
doi: 10.1007/s13238-020-00786-8. Epub 2020 Sep 18.

Pioneer of prostate cancer: past, present and the future of FOXA1

Mona Teng #  1   2 , Stanley Zhou #  1   2 , Changmeng Cai  3 , Mathieu Lupien  4   5   6 , Housheng Hansen He  7   8
Affiliations
Review

Pioneer of prostate cancer: past, present and the future of FOXA1

Mona Teng et al. Protein Cell. 2021 Jan.

Abstract

Prostate cancer is the most commonly diagnosed non-cutaneous cancers in North American men. While androgen deprivation has remained as the cornerstone of prostate cancer treatment, resistance ensues leading to lethal disease. Forkhead box A1 (FOXA1) encodes a pioneer factor that induces open chromatin conformation to allow the binding of other transcription factors. Through direct interactions with the Androgen Receptor (AR), FOXA1 helps to shape AR signaling that drives the growth and survival of normal prostate and prostate cancer cells. FOXA1 also possesses an AR-independent role of regulating epithelial-to-mesenchymal transition (EMT). In prostate cancer, mutations converge onto the coding sequence and cis-regulatory elements (CREs) of FOXA1, leading to functional alterations. In addition, FOXA1 activity in prostate cancer can be modulated post-translationally through various mechanisms such as LSD1-mediated protein demethylation. In this review, we describe the latest discoveries related to the function and regulation of FOXA1 in prostate cancer, pointing to their relevance to guide future clinical interventions.

Keywords: FOXA1; epigenetics; pioneer factor; prostate cancer; transcription factor.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic of FOXA1 activity in (A) normal prostate and (B) prostate cancer. (A) FOXA1 preferentially binds to genomic Forkhead motifs marked by H3K4me1/me2 histone modifications. It induces open chromatin conformation and allows for the sequential binding of AR to drive AR transcriptional programs. FOXA1 also inhibits EMT independent of AR. (B) In prostate cancer, FOXA1 can extensively reprogram AR cistrome along with HOXB13. FOXA1 mutations can result in stronger AR binding and significantly alter AR transcriptional programs. FOXA1 mutants can also induce EMT programs to drive cancer metastasis. Abbreviations: ARE, androgen-receptor response element; EMT, epithelial-mesenchymal transition
Figure 2
Figure 2
Protein map of FOXA1 functional domains and secondary structures. Residues in red represent Wing2 mutational hotspot. FOXA1 methylation site at lysine 270 (K270) is highlighted. Abbreviation: TA, transactivation domain
Figure 3
Figure 3
Noncoding mutations converge onto FOXA1. FOXA1 locus is frequently altered by structural rearrangements inclusive of translocations and tandem duplications. Translocations can result in genes hijacking the activity of the FOXMIND enhancer. In addition, translocations can insert oncogenes upstream of FOXA1. Along with FOXMIND, 5 additional functional CREs harbouring SNVs are identified near FOXA1 locus which can affect the expression of FOXA1. The 3′ UTR region of FOXA1 is frequently mutated with indels being the dominant type of mutation. Abbreviations: SNV, single nucleotide variant; 3′ UTR, 3′ untranslated region; CRE, cis-regulatory elements
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019;571:408–412. - PMC - PubMed
    1. Ahmed M, Sallari RC, Guo H, Moore JH, He HH, Lupien M. Variant Set Enrichment: an R package to identify disease-associated functional genomic regions. BioData Min. 2017;10:9. - PMC - PubMed
    1. American Cancer Society (2019) Cancer Facts & Figures 2019
    1. Annala M, Taavitsainen S, Vandekerkhove G, Bacon JVW, Beja K, Chi KN, Nykter M, Wyatt AW. Frequent mutation of the FOXA1 untranslated region in prostate cancer. Commun Biol. 2018;1:122. - PMC - PubMed
    1. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov. 2012;11:384–400. - PubMed

Publication types

MeSH terms